- Home
- IAUX vs ITOS Comparison
IAUX vs ITOS Comparison
Compare IAUX & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IAUX
- ITOS
- Stock Information
- Founded
- IAUX 2020
- ITOS 2011
- Country
- IAUX United States
- ITOS United States
- Employees
- IAUX N/A
- ITOS N/A
- Industry
- IAUX
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IAUX
- ITOS Health Care
- Exchange
- IAUX Nasdaq
- ITOS Nasdaq
- Market Cap
- IAUX 272.2M
- ITOS 270.7M
- IPO Year
- IAUX N/A
- ITOS 2020
- Fundamental
- Price
- IAUX $0.54
- ITOS $6.67
- Analyst Decision
- IAUX
- ITOS Strong Buy
- Analyst Count
- IAUX 0
- ITOS 3
- Target Price
- IAUX N/A
- ITOS $25.67
- AVG Volume (30 Days)
- IAUX 6.6M
- ITOS 559.5K
- Earning Date
- IAUX 05-05-2025
- ITOS 04-28-2025
- Dividend Yield
- IAUX N/A
- ITOS N/A
- EPS Growth
- IAUX N/A
- ITOS N/A
- EPS
- IAUX N/A
- ITOS N/A
- Revenue
- IAUX $55,970,000.00
- ITOS $35,000,000.00
- Revenue This Year
- IAUX $102.68
- ITOS N/A
- Revenue Next Year
- IAUX $52.24
- ITOS $31.74
- P/E Ratio
- IAUX N/A
- ITOS N/A
- Revenue Growth
- IAUX N/A
- ITOS 177.89
- 52 Week Low
- IAUX $0.34
- ITOS $4.80
- 52 Week High
- IAUX $1.44
- ITOS $18.75
- Technical
- Relative Strength Index (RSI)
- IAUX 37.91
- ITOS 49.00
- Support Level
- IAUX $0.56
- ITOS $6.18
- Resistance Level
- IAUX $0.65
- ITOS $7.80
- Average True Range (ATR)
- IAUX 0.03
- ITOS 0.50
- MACD
- IAUX -0.00
- ITOS -0.05
- Stochastic Oscillator
- IAUX 28.31
- ITOS 29.94
About IAUX i-80 Gold Corp.
i-80 Gold Corp is a well-financed gold and silver producer engaged in the exploration, development, and production of gold, silver, and poly-metallic deposits. The Company's principal assets include the Ruby Hill Mine, Lone Tree Mine, Granite Creek Mine, and McCoy-Cove Project.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.